Related Experiment Video
Updated: Jul 19, 2025
10:44
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
13.3K
The Bivalent Bromodomain Inhibitor MT-1 Inhibits Prostate Cancer Growth
Sanjeev Shukla1, Carlos Riveros1, Mohammed Al-Toubat1
1Department of Urology, University of Florida Health, Jacksonville, FL 32209, USA.
Cancers
|August 12, 2023
Summary
A novel bromodomain inhibitor, MT-1, effectively targets c-Myc in prostate cancer (PC) cells, reducing viability and tumor growth. This preclinical study highlights MT-1
Area of Science:
- Epigenetics and Molecular Biology
- Cancer Therapeutics
- Prostate Cancer Research
Background:
- Bromodomains (BD) are epigenetic readers regulating gene transcription, including the proto-oncogene c-Myc.
- c-Myc upregulation is implicated in advanced prostate cancer (PC), posing a therapeutic challenge due to its structure and localization.
- Targeting c-Myc via epigenetic mechanisms offers a promising strategy for PC treatment.
Purpose of the Study:
- To evaluate the efficacy of MT-1, a potent bivalent bromodomain inhibitor, against c-Myc dysregulation in prostate cancer.
- To assess MT-1's effects on PC cell viability, cell cycle, and downstream molecular targets.
- To investigate MT-1's therapeutic potential in preclinical models of advanced, treatment-resistant prostate cancer.
Main Methods:
- Treatment of PC cell lines and patient-derived xenograft (PDX) models with MT-1.
- Assessment of cell viability, cell cycle progression (G0/G1 arrest), and c-Myc inhibition.
- Molecular analysis of c-Myc downstream targets including Protein Kinase D1 (PrKD) and its substrates.
- Evaluation of MT-1 efficacy in 3D cultures and orthotopic mouse models, including combination therapy with a MAX inhibitor.
Main Results:
- MT-1 demonstrated dose-dependent reduction in PC cell viability and induced G0/G1 cell cycle arrest.
- MT-1 treatment led to de-repression of PrKD and altered phosphorylation of key substrates, confirming c-Myc inhibition.
- Lowest IC50 values for MT-1 were observed in PC PDX models with c-Myc amplification and resistance to standard therapies.
- MT-1, alone or in combination with a MAX inhibitor, significantly reduced tumor growth in orthotopic PC PDX mouse models.
Conclusions:
- MT-1 is a potent bromodomain inhibitor effective against c-Myc dysregulation in prostate cancer.
- MT-1 exhibits preclinical efficacy in models of advanced, treatment-resistant prostate cancer.
- This study establishes MT-1 as a potential therapeutic agent for c-Myc-driven prostate cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:38Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
01:15Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K